Company / SG&A Expense
ARDELYX, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$337.2M
FY2025
5-year range
$72.3M / $337.2M
FY2021-FY2025
Trend
+30.4%
vs FY2024
Sector context
#51 of 213
Health Care
What the data says
ARDELYX, INC.'s sg&a expense of $337M is higher than 76% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 9 consecutive years, from $7M in FY2016 to $337M in FY2025.
Based on SEC 10-K filings.
$337M in FY2025 with a 5-year CAGR of +59.0%. Top quartile in the Health Care sector.
Increased from $134M to $337M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +63.9%
- 5-Year CAGR
- +59.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 213This company $337.2M Sector average $722.3M
▼
-53.3% below sector average
Key checks
Key Insights
- ARDELYX, INC.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +59.0%, indicating consistent growth.
- In FY2025, sg&a expense increased 30.4% year-over-year.
- Ranks #51 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $337.2M | +30.4% |
| FY2024 | $258.7M | +92.5% |
| FY2023 | $134.4M | +75.5% |
| FY2022 | $76.6M | +5.9% |
| FY2021 | $72.3M | +118.1% |
| FY2020 | $33.2M | +36.6% |
| FY2019 | $24.3M | +2.3% |
| FY2018 | $23.7M | +75.3% |
| FY2017 | $13.5M | +85.7% |
| FY2016 | $7.3M | -46.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026